| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma
|
Zhao, Donghua
|
|
|
155 |
C |
p. 193-195
|
artikel
|
| 2 |
Contents
|
|
|
|
155 |
C |
p. v-vii
|
artikel
|
| 3 |
Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer
|
Furukawa, Rie
|
|
|
155 |
C |
p. 144-150
|
artikel
|
| 4 |
Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study
|
Lv, Wenhui
|
|
|
155 |
C |
p. 78-86
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
155 |
C |
p. iii
|
artikel
|
| 6 |
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer
|
Yoh, Kiyotaka
|
|
|
155 |
C |
p. 40-45
|
artikel
|
| 7 |
Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study
|
Wang, Wenxian
|
|
|
155 |
C |
p. 20-27
|
artikel
|
| 8 |
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L)
|
Garcia Campelo, Maria Rosario
|
|
|
155 |
C |
p. 68-77
|
artikel
|
| 9 |
Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes
|
Forest, Fabien
|
|
|
155 |
C |
p. 1-9
|
artikel
|
| 10 |
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging
|
van de Stadt, Eveline A.
|
|
|
155 |
C |
p. 156-162
|
artikel
|
| 11 |
Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer
|
Moraes, Fabio Y.
|
|
|
155 |
C |
p. 34-39
|
artikel
|
| 12 |
Metabolomic profiling for second primary lung cancer: A pilot case-control study
|
Aredo, Jacqueline V.
|
|
|
155 |
C |
p. 61-67
|
artikel
|
| 13 |
Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease
|
Tasaka, Yuri
|
|
|
155 |
C |
p. 120-126
|
artikel
|
| 14 |
Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres
|
Bissonnette, Jean-Pierre
|
|
|
155 |
C |
p. 136-143
|
artikel
|
| 15 |
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison
|
Halmos, Balazs
|
|
|
155 |
C |
p. 175-182
|
artikel
|
| 16 |
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
|
Park, Keunchil
|
|
|
155 |
C |
p. 127-135
|
artikel
|
| 17 |
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study
|
Epaillard, Nicolas
|
|
|
155 |
C |
p. 114-119
|
artikel
|
| 18 |
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
|
Noordhof, A.L.
|
|
|
155 |
C |
p. 163-169
|
artikel
|
| 19 |
Psychosocial consequences of a three-month follow-up after receiving an abnormal lung cancer CT-screening result: A longitudinal survey
|
Damhus, Christina Sadolin
|
|
|
155 |
C |
p. 46-52
|
artikel
|
| 20 |
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors
|
Liu, Jia
|
|
|
155 |
C |
p. 28-33
|
artikel
|
| 21 |
Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease
|
Arrieta, Oscar
|
|
|
155 |
C |
p. 183-190
|
artikel
|
| 22 |
Role of dietary carbohydrates on risk of lung cancer
|
Tao, Jun
|
|
|
155 |
C |
p. 87-93
|
artikel
|
| 23 |
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189
|
Garon, Edward B.
|
|
|
155 |
C |
p. 53-60
|
artikel
|
| 24 |
Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment
|
Sumi, Toshiyuki
|
|
|
155 |
C |
p. 196-198
|
artikel
|
| 25 |
Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation
|
Moreno-Ruiz, Pablo
|
|
|
155 |
C |
p. 10-19
|
artikel
|
| 26 |
The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis
|
Yun, Jae Kwang
|
|
|
155 |
C |
p. 94-102
|
artikel
|
| 27 |
The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events
|
Osarogiagbon, Raymond U.
|
|
|
155 |
C |
p. 191-192
|
artikel
|
| 28 |
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort
|
Moreno, Victor
|
|
|
155 |
C |
p. 151-155
|
artikel
|
| 29 |
Trends and variations in treatment of stage I–III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands
|
Evers, Jelle
|
|
|
155 |
C |
p. 103-113
|
artikel
|
| 30 |
Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib
|
Luo, Yuxi
|
|
|
155 |
C |
p. 170-174
|
artikel
|
Tijdschrift beschrijving